

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
2 June 2005 (02.06.2005)

PCT

(10) International Publication Number
WO 2005/049846 A3

(51) International Patent Classification⁷: C12N 15/869,
A61K 35/76, C12N 7/01, C07K 14/82, C12N 15/11,
A61K 48/00

(21) International Application Number:
PCT/GB2004/004908

(22) International Filing Date:
17 November 2004 (17.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0326798.6 17 November 2003 (17.11.2003) GB
60/541,308 3 February 2004 (03.02.2004) US

(71) Applicants (for all designated States except US):
CRUSADE LABORATORIES LIMITED [GB/GB];
PO Box 1716, Glasgow Strathclyde G51 4WF (GB).
**SLOANE-KETTERING INSTITUTE FOR CANCER
RESEARCH** [US/US]; Memorial Sloan Kettering Can-
cer Center, 1275 York Avenue, New York, New York
10021 (US).

(71) Applicants and


(72) Inventors: **BROWN, Susanne Moira** [GB/GB]; Crusade
Laboratories Limited, PO Box 1716, Glasgow Strathclyde
G51 4WF (GB). **DUNN, Paul** [GB/GB]; Crusade Labo-
ratories Limited, PO Box 1716, Glasgow Strathclyde G51
4WF (GB). **SINGH, Bhuvanesh** [US/US]; 86-79 Sancho
Street, Holliswood, New York, New York 11423 (US).
GANLY, Ian [GB/US]; 504 East 63rd Street, Apartment
26S, New York, New York 10021 (US).

(74) Agents: **CLEGG, Richard** et al.; Mewburn Ellis LLP,
York House, '23 Kingsway, London Greater London
WC2B 6HP (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

[Continued on next page]

(54) Title: **MUTANT HERPES SIMPLEX VIRUS AND USE THEREOF IN THE TREATMENT OF SQUAMOUS CELL CAN-
CER**



(57) Abstract: An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses.



(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
6 October 2005

Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.